Should public health leaders get on the genomics train?
Tier 1 genomic applications, backed by strong evidence of their clinical utility, support population screening to identify those at heightened risk for inherited cancers and cardiovascular disease. While accounting for less than 10% of the population, these individuals and families account for disproportionate morbidity and mortality and can benefit from targeted prevention efforts.